June 22, 2026
All News
June 22, 2026
NRG Oncology Health Care Access Symposium Calls on Research Community to Advance Trial Accessibility
Read MoreJune 22, 2026
The Importance of Survivorship and Supportive Care Research: Interviews with Drs. Peterson and Tippey
Read MoreMay 29, 2026
Addition of Immunotherapy Continues to Show Survival Benefit in Prolonged Follow-up in NRG Oncology Trial for Primary Advanced Stage or Recurrent Endometrial Cancer
Read MoreMay 12, 2026
Assessing Adaptive Radiotherapy and Chemotherapy for Muscle-Invasive Bladder Cancer (NRG-GU015, The ARCHER Trial)
Read MoreMay 12, 2026
Reena Cecchini, PhD, Promoted to Research Associate Professor at the University of Pittsburgh
Read MoreMay 12, 2026
Testing Immunotherapy with Radiation Therapy for Patients with High-Risk, T1 Bladder Cancer (NRG-GU014, The PARRC Trial)
Read MoreApril 15, 2026
NRG-HN016 (CONCISE): New NRG Oncology Pragmatic Phase 3 Trial for Cisplatin-Ineligible Locoregionally Advanced Head & Neck Cancer Launching Soon!
Read MoreApril 15, 2026